Alverno Laboratories chooses Ibex’s AI-based cancer diagnostics solution

Ibex harnesses artificial intelligence to enable real-time cancer diagnostics | Photo: ibex Medical Analytics

Diagnostic testing services provider Alverno Laboratories and AI-based cancer diagnostics provider Ibex Medical Analytics have closed a deal to deploy Ibex’s AI-powered Galen platform, the companies announced Wednesday.

Ibex transforms cancer diagnosis by harnessing Strong AI and machine learning technology. Ibex’s Galen platform helps pathologists improve the quality of cancer diagnosis, implement real-time quality control1, reduce diagnosis time and boost productivity. The platform was recently granted Breakthrough Device Designation by the US Food and Drug Administration (FDA) and is CE marked in Europe for breast and prostate cancer detection in multiple workflows.

Alverno is among the first labs in the US to implement digital pathology technologies. By adding Ibex’s Galen platform, pathologists at Alverno can be expected to benefit from clinical-grade AI insights available on different workflows and multiple types of tissue.

“We are thrilled to team up with Alverno and enable their pathologists to use state-of-the-art AI solutions to accurately detect cancer and improve quality and efficiency of diagnosis,” said Joel Duckworth, Chief Revenue Officer for the Americas at Ibex. “With this roll out, Alverno is setting a new standard in cancer care quality.”